Arcus Capital Partners’s Q32 Bio QTTB Stock Holding History

Arcus Capital Partners’s Portfolio QTTB Stock Details QTTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43	Closed	-$968	–	366
2022 Q4	$968	Buy	+43	New	+$1.14K	﹤0.01%	335

Other funds holding QTTB

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Arcus Capital Partners's QTTB Position: Q1 2023 in Review

Arcus Capital Partners sold out of Q32 Bio (QTTB) in Q1 2023, closing a stake of 43 shares — an estimated $968 sold.

Arcus Capital Partners first reported a position in QTTB in Q4 2022 and held it in 1 quarter. The position peaked at $968 in Q4 2022. 62 funds tracked by Wall St. Rank hold QTTB as of Q1 2023.

Arcus Capital Partners reported no remaining Q32 Bio position as of Q1 2023 after selling out during the quarter.
Arcus Capital Partners sold 43 Q32 Bio shares in Q1 2023, an estimated $968.
Arcus Capital Partners first reported a position in Q32 Bio in Q4 2022 and held it in 1 quarter.
Arcus Capital Partners's Q32 Bio position peaked at $968 in Q4 2022.
62 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2023.

Based on Arcus Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.